Segment Information (Tables)

9 Months Ended

Mar. 31, 2014

Financial Information Relating to Reportable Segments

Following is financial information relating to the Company’s reportable segments (in thousands):

	Quarter Ended						Nine Months Ended
	March 31,						March 31,
	2014			2013			2014			2013
External sales
Biotechnology	$	80,134		$	75,285		$	223,881		$	214,416
Clinical Controls		15,421			5,707			41,359			16,684
Consolidated net sales	$	95,555		$	80,992		$	265,240		$	231,100
Earnings before income taxes
Biotechnology	$	44,593		$	43,246		$	120,589		$	117,123
Clinical Controls		3,157			2,247			7,225			6,498
Segment earnings before income taxes		47,750			45,493			127,814			123,621
Unallocated corporate expenses and equity method investee losses		(1,681	)		(1,027	)		(5,873	)		(3,723	)
Consolidated earnings before income taxes	$	46,069		$	44,466		$	121,941		$	119,898